Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma
Open Access
- 2 August 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 46 (5), 764-765
- https://doi.org/10.1038/bmt.2010.180
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)Blood, 2010
- The role of complete response in multiple myelomaBlood, 2009
- A364 A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in MyelomaClinical Lymphoma Myeloma and Leukemia, 2009
- Treatment of acquired aplastic anemiaHaematologica, 2007
- The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation studyBritish Journal of Haematology, 2006
- International uniform response criteria for multiple myelomaLeukemia, 2006
- The Proteasome — An Emerging Therapeutic Target in CancerNew England Journal of Medicine, 2003
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003